Literature DB >> 32610339

Activation of peroxisome proliferator-activated receptor γ reduces alcohol drinking and seeking by modulating multiple mesocorticolimbic regions in rats.

Yannick Fotio1,2, Anna Maria Borruto1, Federica Benvenuti1, Gregory Demopulos3, George Gaitanaris3, Marisa Roberto4, Roberto Ciccocioppo5.   

Abstract

Peroxisome proliferator-activated receptor γ (PPARγ) is an intracellular transcription factor whose signaling activation by the selective agonist pioglitazone reduces alcohol drinking and alcohol-seeking behavior in rats. The present study utilized the two-bottle choice and operant self-administration procedures to investigate neuroanatomical substrates that mediate the effects of PPARγ agonism on alcohol drinking and seeking in msP rats. Bilateral infusions of pioglitazone (0, 5, and 10 μg/μl) in the rostromedial tegmental nucleus (RMTg) decreased voluntary alcohol drinking and alcohol self-administration. Microinjections of pioglitazone in the ventral tegmental area (VTA), central amygdala (CeA), and nucleus accumbens (NAc) shell had no such effect. Notably, water, food, and saccharin consumption was unaltered by either treatment. The yohimbine-induced reinstatement of alcohol seeking was prevented by infusions of pioglitazone (0, 2.5, 5, and 10 μg/μl) in the CeA, VTA, and RMTg but not in the NAc shell. These results emphasize the involvement of mesocorticolimbic circuitries in mediating the effects of PPARγ agonists on alcohol drinking and seeking. These results will facilitate future studies that investigate the pathophysiological role of PPARγ in alcohol use disorder and help clarify the mechanisms by which the activation of this receptor decreases the motivation for drinking.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32610339      PMCID: PMC7852659          DOI: 10.1038/s41386-020-0754-4

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  60 in total

1.  Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking.

Authors:  Serena Stopponi; Lorenzo Somaini; Andrea Cippitelli; Nazzareno Cannella; Simone Braconi; Marsida Kallupi; Barbara Ruggeri; Markus Heilig; Gregory Demopulos; George Gaitanaris; Maurizio Massi; Roberto Ciccocioppo
Journal:  Biol Psychiatry       Date:  2011-01-31       Impact factor: 13.382

Review 2.  DSM-5 criteria for substance use disorders: recommendations and rationale.

Authors:  Deborah S Hasin; Charles P O'Brien; Marc Auriacombe; Guilherme Borges; Kathleen Bucholz; Alan Budney; Wilson M Compton; Thomas Crowley; Walter Ling; Nancy M Petry; Marc Schuckit; Bridget F Grant
Journal:  Am J Psychiatry       Date:  2013-08       Impact factor: 18.112

3.  PPARbeta/delta potentiates PPARgamma-stimulated adipocyte differentiation.

Authors:  Kimihiko Matsusue; Jeffrey M Peters; Frank J Gonzalez
Journal:  FASEB J       Date:  2004-07-09       Impact factor: 5.191

Review 4.  Neurobiology of alcohol dependence: focus on motivational mechanisms.

Authors:  Nicholas W Gilpin; George F Koob
Journal:  Alcohol Res Health       Date:  2008

5.  Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis.

Authors:  David A Sarruf; Fang Yu; Hong T Nguyen; Diana L Williams; Richard L Printz; Kevin D Niswender; Michael W Schwartz
Journal:  Endocrinology       Date:  2008-10-09       Impact factor: 4.736

6.  Activation of PPARγ by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats.

Authors:  Serena Stopponi; Giordano de Guglielmo; Lorenzo Somaini; Andrea Cippitelli; Nazzareno Cannella; Marsida Kallupi; Massimo Ubaldi; Markus Heilig; Gregory Demopulos; George Gaitanaris; Roberto Ciccocioppo
Journal:  Alcohol Clin Exp Res       Date:  2013-03-29       Impact factor: 3.455

Review 7.  Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation.

Authors:  Sonia Villapol
Journal:  Cell Mol Neurobiol       Date:  2017-10-03       Impact factor: 5.046

Review 8.  ALCOHOL DEPENDENCE--NEUROBIOLOGY AND TREATMENT.

Authors:  Agnieszka Michalak; Grazyna Biała
Journal:  Acta Pol Pharm       Date:  2016 Jan-Feb       Impact factor: 0.330

Review 9.  Review of the Structural and Dynamic Mechanisms of PPARγ Partial Agonism.

Authors:  Alice J Kroker; John B Bruning
Journal:  PPAR Res       Date:  2015-09-08       Impact factor: 4.964

10.  Localization of PPAR isotypes in the adult mouse and human brain.

Authors:  Anna Warden; Jay Truitt; Morgan Merriman; Olga Ponomareva; Kelly Jameson; Laura B Ferguson; R Dayne Mayfield; R Adron Harris
Journal:  Sci Rep       Date:  2016-06-10       Impact factor: 4.379

View more
  4 in total

1.  Yohimbine as a pharmacological probe for alcohol research: a systematic review of rodent and human studies.

Authors:  Dallece E Curley; Talia R Vasaturo-Kolodner; Nazzareno Cannella; Roberto Ciccocioppo; Carolina L Haass-Koffler
Journal:  Neuropsychopharmacology       Date:  2022-06-27       Impact factor: 8.294

2.  Andrographis paniculata and Its Main Bioactive Ingredient Andrographolide Decrease Alcohol Drinking and Seeking in Rats Through Activation of Nuclear PPARγ Pathway.

Authors:  Serena Stopponi; Yannick Fotio; Carlo Cifani; Hongwu Li; Carolina L Haass-Koffler; Nazzareno Cannella; Gregory Demopulos; George Gaitanaris; Roberto Ciccocioppo
Journal:  Alcohol Alcohol       Date:  2021-02-24       Impact factor: 2.826

Review 3.  Genetically selected alcohol-preferring msP rats to study alcohol use disorder: Anything lost in translation?

Authors:  Anna Maria Borruto; Serena Stopponi; Hongwu Li; Friedbert Weiss; Marisa Roberto; Roberto Ciccocioppo
Journal:  Neuropharmacology       Date:  2021-01-18       Impact factor: 5.273

Review 4.  Immune treatments for alcohol use disorder: A translational framework.

Authors:  Lindsay R Meredith; Elizabeth M Burnette; Erica N Grodin; Michael R Irwin; Lara A Ray
Journal:  Brain Behav Immun       Date:  2021-07-31       Impact factor: 19.227

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.